Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 31st total of 1,420,000 shares. Based on an average daily trading volume, of 4,600,000 shares, the short-interest ratio is presently 0.3 days. Approximately 3.3% of the shares of the company are short sold.

Athira Pharma Price Performance

Shares of ATHA stock traded down $0.01 during trading hours on Friday, reaching $0.53. 184,809 shares of the company were exchanged, compared to its average volume of 209,871. The stock’s fifty day moving average is $0.58 and its two-hundred day moving average is $1.23. Athira Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $4.30. The company has a market cap of $20.31 million, a price-to-earnings ratio of -0.18 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. On average, research analysts anticipate that Athira Pharma will post -2.35 earnings per share for the current year.

Hedge Funds Weigh In On Athira Pharma

A number of hedge funds have recently bought and sold shares of ATHA. American Century Companies Inc. raised its stake in shares of Athira Pharma by 9.4% during the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the period. Renaissance Technologies LLC grew its position in shares of Athira Pharma by 3.5% during the 2nd quarter. Renaissance Technologies LLC now owns 271,488 shares of the company’s stock valued at $719,000 after acquiring an additional 9,164 shares during the period. XTX Topco Ltd purchased a new stake in Athira Pharma in the second quarter worth $60,000. Invst LLC bought a new stake in Athira Pharma in the 2nd quarter valued at about $68,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Athira Pharma by 25.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after buying an additional 111,759 shares in the last quarter. Institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.